Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.


Business Profile

  • Brieflands is a Registered Trademark with record number 1454012.
  • Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
  • Nedmedica is our related company which is specialized in Author Services. 
  • Our former branding name was Kowsarmedical Publishing (2010-2021).
 

Recent Submissions

Item
Effect of Oral Synbiotic Consumption on Glycemic Control and Honeymoon Phase Duration in Children with Type 1 Diabetes: A Randomized Clinical Trial
(Brieflands, 2025-08-31) Sara Nikpour; Nosrat Ghaemi; Nasrin Moazzen; Sepideh Bagheri; Samaneh Noroozi Asl; Hamid Ahanchian; Tahereh Sadeghi; Nasrin Moazzen [0000-0001-8129-671X]; Hamid Ahanchian [0000-0003-3532-7428]; Tahereh Sadeghi [0000-0002-4396-2707]
Background: The present study aimed to investigate the effects of synbiotics on glycemic control and the duration of the honeymoon phase in newly diagnosed children with type 1 diabetes mellitus (T1DM). Methods: This study is a randomized, triple-blind clinical trial conducted in Mashhad in 2023. The samples included children aged 2 to 18 years who were referred to the Endocrinology Clinic of Akbar Children’s Hospital. The patients were randomly divided into two groups: Synbiotic and placebo (60 participants in each group). The synbiotic group received capsules containing specific strains of Lactobacillus, Bifidobacterium, and Streptococcus thermophiles, while the placebo group received a placebo for six months. Blood sugar control indices, HbA1c, and lipid profiles were recorded at the beginning of the study and then at three-month intervals. The duration of the honeymoon period and the number of diabetic ketoacidosis attacks during treatment were also examined. Patients were followed up every three months for one year. Data were analyzed using SPSS version 22 software, and a 95% confidence level was considered. Results: After six months, the synbiotic group showed a significant decrease in total daily insulin dose compared to the placebo group (P = 0.000). No significant differences were observed in mean HbA1c levels between the two groups before the study and three months after synbiotic consumption (P > 0.05). However, after the six-month follow-up, the synbiotic group demonstrated a significant decrease in HbA1c levels (P = 0.039). At the end of the six months, the percentage of participants in the honeymoon phase differed significantly between the two groups, with 3.3% in the placebo group and 13.3% in the synbiotic group (P = 0.048). Conclusions: Synbiotic supplementation in children with T1DM can lead to improvements in glycemic control, including reduced insulin requirements, enhanced HbA1c levels, and a prolonged honeymoon phase. These outcomes highlight the potential of synbiotics as a supportive adjunct to standard diabetes management strategies for improving glycemic control in this population.
Item
The Proportion of PNPLA3 rs738409 GG Homozygous in Different Populations and Its Impact on Fibrosis Progression in Biopsy-Proven NAFLD Patients: Meta-Analysis and Systematic Review
(Brieflands, 2025-12-31) Shuixian Du; Jianhong Yin; Kezhen Hu; Yongning Xin
Context: Some studies have reported that the phospholipase domain-containing protein 3 (PNPLA3) rs738409 GG homozygous genotype is associated with increased risk of liver disease severity in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). Given the increasing global prevalence of NAFLD and the lack of definitive treatment for non-alcoholic steatohepatitis (NASH) or a first-line therapy for NAFLD, many researchers are seeking a cure for NASH in individuals with NAFLD who have the rs738409 GG homozygous genotype. Objectives: We conducted a systematic review and meta-analysis to assess the proportion of PNPLA3 rs738409 GG homozygous individuals in different populations and its impact on fibrosis progression in biopsy-proven NAFLD patients, to support data basis for Precision Gene Therapy of NAFLD. Methods: PubMed, Cochrane Library, and Embase Database were searched for case-control studies from inception to July 3, 2024. The following keywords were used: Fatty liver, PNPLA3, and rs738409 gene or variants or polymorphism or alleles. A meta-analysis and systematic review were conducted utilizing the articles retrieved. Results: A total of 13 eligible studies and 3823 people were included in this study. The pooled PNPLA3 rs738409 GG homozygous proportion of NAFLD was estimated to be 30% (95% CI: 0.22 - 0.37) in adults, 24% (95% CI: 0.15 - 0.33) in adolescents, 33% (95% CI: 0.26 - 0.39) in the Asian population, 39% (95% CI: 0.32 - 0.47) in Japanese, and 25% (95% CI: 0.22 - 0.28) in Chinese. Advanced fibrosis (≥ 2) was estimated to be 11% (95% CI: 0.07 - 0.16) in adults, 11% (95% CI: 0.06 - 0.16) in the Asian population, and 15% (95% CI: 0.07 - 0.23) in Japanese. Two articles from the Chinese population showed that advanced fibrosis (≥ 2) was estimated to be 5.9% and 4.8%. Our results showed that the incidence of GG homozygous in patients with advanced fibrosis (≥ 2) had a 1.27-fold and 1.24-fold greater proportion compared with low-level fibrosis (< 2) in adult and Asian populations, respectively. Conclusions: The rs738409 GG homozygous proportion in biopsy-proven NAFLD varies due to geographic and population heterogeneity. Our results showed that rs738409 GG homozygous exerts a strong influence on developing fibrosis.
Item
Non-alcoholic Fatty Liver in Patients with Gallstones Undergoing Cholecystectomy
(Brieflands, 2025-12-31) Mehdi Hashemi; Samaneh Adineh; Yousef Paridar; Aziz Kassani; Mehdi Hashemi [0000-0001-7174-3651]; Samaneh Adineh [0000-0002-7943-2820]; Yousef Paridar [0000-0001-9727-4048]; Aziz Kassani [0000-0001-5188-5249]
Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition often associated with metabolic syndrome and gallstone disease (GSD). Objectives: The present study aimed to investigate symptomatic gallstone patients undergoing cholecystectomy. Methods: This cross-sectional study included 330 patients who underwent cholecystectomy at the Referral Hospital of Ganjavian in Dezful city, Iran, between 2020 and 2022. Patients were selected using simple random sampling. Inclusion criteria were patients aged 18 - 85 with symptomatic gallstones (GS), while exclusion criteria comprised other liver diseases. Data on age, gender, NAFLD (assessed by ultrasonography), liver enzymes, and comorbidities were collected. Results: Among the 330 patients, 31.82% (n = 105) were diagnosed with NAFLD. The mean age of the patients was 48.64 ± 13.48 years. The NAFLD was significantly associated with diabetes (OR = 2.97, 95% CI: 1.61 - 5.45), dyslipidemia (OR = 1.96, 95% CI: 1.13 - 3.37), and hypertension (OR = 2.12, 95% CI: 1.24 - 3.61). There was a significant difference between patients with NAFLD and those without NAFLD (P < 0.05). Conclusions: This study identified a significant prevalence of NAFLD at 31.82% among symptomatic gallstone patients undergoing cholecystectomy. The incidence of NAFLD showed no correlation with gender or smoking status; however, it was strongly associated with various metabolic comorbidities. These findings highlight the necessity for a comprehensive approach to managing GSD, including early detection and targeted treatment of NAFLD and its related metabolic conditions.
Item
Predictive Role of Pentraxin-3 (PTX-3) in IgA Vasculitis Nephritis: Insights from a Prospective Study
(Brieflands, 2025-07-09) Selcuk Yuksel; Selcuk Yuksel [0000-0001-9415-1640]
This article does not have an abstract.
Item
Psychometric Validation of the Hypersexual Behavior Scale in University Students in Bandar Abbas, Southern Iran
(Brieflands, 2025-06-10) Somayeh Shahbazian; Azita Amirfakhraei; Shahrzad Sanjari; Somayeh Shahbazian [0009-0003-1280-6589]; Azita Amirfakhraei [0000-0002-8064-4660]; Shahrzad Sanjari [0000-0002-8773-5637]
Background: Hypersexual behavior represents a significant psychological concern that may adversely affect mental health and interpersonal relationships. Objectives: In line with the study title, this research aimed to perform a psychometric evaluation and validation of the Hypersexual Behavior Scale (HBS) in university students in Bandar Abbas, Southern Iran. Methods: This cross-sectional psychometric study (2023 - 2024) involved 1250 students from five universities in Bandar Abbas — Hormozgan University, Hormozgan University of Medical Sciences, Islamic Azad University, Payame Noor University, and Rezavi Institute — selected via stratified random sampling. Conducted without financial support, the study followed ethical standards approved by the Ethics Committee of Islamic Azad University, Bandar Abbas Branch, and had prior research council approval (September 11, 2023). Undergraduate and postgraduate students participated voluntarily with informed consent; incomplete responses were excluded. The sample size met psychometric requirements: ≥ 400 for exploratory factor analysis (EFA) and ≥ 200 for confirmatory factor analysis (CFA), concurrent validity, and reliability. Results: Demographic characteristics indicated that 62.2% of the participants were female (n = 777) and 37.8% were male (n = 473), with a mean age of 22.1 years (standard deviation [SD] = 2.4). Excellent content validity was reported, and the concurrent validity with the HBI was strong (r = 0.56, P < 0.001). Exploratory factor analysis extracted five factors accounting for 57.95% of the variance, which was confirmed by CFA with root mean square error of approximation (RMSEA) = 0.064 and Comparative Fit Index (CFI) = 0.98. Overall reliability was high (α = 0.959; split-half reliability = 0.909; test-retest r = 0.89). The ROC analysis identified a cut-off point of 61 as optimal with Youden’s Index (J) = 0.989 (sensitivity = 0.989; specificity = 1.000). Conclusions: The HBS scale is a valid and reliable instrument for assessing high-risk sexual behaviors among university students in Bandar Abbas, Southern Iran. However, the cross-sectional design, reliance on self-reported data, and sampling from a single city may have intensified selection and reporting biases, thereby limiting the generalizability of the results to other regions and age groups.